Loading news...
Aquatic Capital Management LLC raised its holdings in shares of Bruker Corporation (NASDAQ: BRKR) by 120.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 349,596 shares of the medical research company's stock after buying an additional
Citigroup Inc. trimmed its stake in shares of Bruker Corporation (NASDAQ: BRKR) by 32.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 61,838 shares of the medical research company's stock after selling 29,083 shares during the quarter. Citigroup Inc.'s holdings in
DNB Asset Management AS grew its holdings in Bruker Corporation (NASDAQ: BRKR) by 40.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 143,257 shares of the medical research company's stock after acquiring an additional 41,289 shares during the period. DNB
Becker Capital Management Inc. grew its position in shares of Bruker Corporation (NASDAQ: BRKR) by 606.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 301,155 shares of the medical research company's stock after purchasing an additional 258,545 shares during the period. Becker
ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical.
ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications. “Noet.
ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker's category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities,.
ST. LOUIS--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants. New releases in Bruker ProteoScape™, OmniScape™, and GlycoScape™ software now support database-independent PTM discovery, confident proteoform characterizatio.
Examine the evolution of Bruker's (BRKR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
BRKR's Q4 EPS miss estimates as margins plunge and shares fall 2.7% despite a revenue beat, while the 2026 outlook targets 4%-5% sales growth.
Bruker Corp (NASDAQ: BRKR) reported mixed fourth-quarter financial results on Thursday.
Bruker Corporation (BRKR) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Bruker (BRKR) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bruker (BRKR) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.76 per share a year ago.
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025. Frank H. Laukien, Bruker's President and CEO, commented: “At the conclusion of a difficult year 2025, with headwinds from academic funding, tariffs and currencies, we are pleased that in the fourth quarter we delivered revenues ahead of our expectations. A recovery in biopharma and industrial research markets in the second h.
Insights from the Fourth Quarter 2025 13F Filing PRIMECAP Management (Trades, Portfolio) recently submitted its 13F filing for the fourth quarter of 2025, offe
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native‑state assessment of bio-nanoparticl.
BOSTON--(BUSINESS WIRE)---- $BRKR #BRKR--At SLAS2026, Chemspeed Technologies, a leader in the automation and digitalization of R&D and QC laboratories, and SciY, a leader in scientific and laboratory management software focused on lab standardization and AI-readiness, today introduce their open Self‑Driving Lab (SDL) platform. Their Self-Driving Lab platform is designed to accelerate research and development (R&D), quality control (QC) and chemical and biomolecular manufacturing workflows. The SDL enab.
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR, BRKRP) today announced that its Board of Directors (“Board”) has approved payment of a quarterly cash dividend in the amount of $3.9844 per share on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock Dividend”). The Mandatory Convertible Preferred Stock Dividend will be paid on March 2, 2026 to stockholders of record as of February 15, 202.
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.